Dyax Corp (DYAX.W)
3.48USD
28 Jan 2010
$-0.16 (-4.73%)
$3.48
--
$3.42
$3.21
228,428
391,869
$4.69
$1.55
DYAX.W
About
Overall
| Beta: | 1.88 |
| Market Cap (Mil.): | $251.32 |
| Shares Outstanding (Mil.): | 78.05 |
| Annual Dividend: | 0.00 |
| Yield (%): | NA |
Financials
| DYAX.W | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 11.50 | 3.76 |
| EPS (TTM): | 44.64 | -- | -- |
| ROI: | -122.67 | 1.25 | 2.30 |
| ROE: | -- | 2.09 | 2.82 |
Cubist Pharma halts enrollment in trials on safety concerns
Dec 3 (Reuters) - Cubist Pharmaceuticals Inc said it suspended enrollment in two mid-stage trials of its experimental treatment to reduce bleeding in on-pump cardiac surgery, after certain data from one trial showed a higher rate of death.
UPDATE 1-Dyax shrs soar after FDA approves genetic-disorder drug
(Adds more analyst comment, details; updates stock movement)
UPDATE 1-Dyax gets FDA marketing nod on genetic disease drug
* Says Kalbitor to treat patients 16 yrs of age and older
UPDATE 1-Sanofi to buy Dyax's drug development partner
* Says Sanofi also in licensing deal with a licensee of Dyax
HEADLINE STOCKS-Some U.S. stocks on the move on Aug. 27
(Updates to afternoon trading, adds Geron, OSI Systems, OshKosh, NCI Building, Immunomedics, Precision Castparts, TiVo, Jackson Hewitt, A-Power, Whiting and Gerber)
HEADLINE STOCKS-Some U.S. stocks on the move on Aug. 27
(Updates to after the open, adds Boeing, Energy Conversion, China Sunergy, NYSE Euronext/NYFIX, Vimplecom, ATS Medical)
HEADLINE STOCKS-Some U.S. stocks to watch on Aug. 27
NEW YORK, Aug 27 (Reuters) - Some U.S. stocks to watch on Thursday:
UPDATE 1-Dyax to raise $14 mln in public share offering
June 25 (Reuters) - Dyax Corp said it would sell 7.4 million common shares at $2.02 a share in an underwritten public offering with no warrants, and expects to raise net proceeds of about $14 million.
UPDATE 2-Dyax says FDA accepts genetic-disease drug response
* Shares up as much as 22 pct (Adds analyst's comments, late-stage study details, updates share movement)
UPDATE 3-FDA asks for additional study on ViroPharma HAE drug
* Dyax shares rise up to 15 pct (Adds analyst, CEO comment; background; adds closing share price)
Competitors
| Price | Change | |
|---|---|---|
| ViroPharma Incorporated (VPHM.OQ) | $9.74 | +0.35 |
| Shire Plc. (SHP.L) | £1,247.00 | +11.00 |
| Shire Plc. (3159084.L) | -- | -- |
| Jerini AG (JI4G.DE) | -- | -- |
| Pharming Group N.V. (PHAR.AS) | €0.46 | +0.00 |
| Novo Nordisk A/S (NOVOb.CO) | kr.375.30 | -2.40 |
| The Medicines Company (MDCO.OQ) | $7.66 | +0.25 |
| Medarex inc. (MEDX.OQ) | -- | -- |
| Genmab A/S (GEN.CO) | kr.93.95 | -3.55 |
| PDL BioPharma Inc. (PDLI.OQ) | $6.64 | +0.09 |
Earnings vs 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
